Radiopharm Theranostics (RDPTF) Net Income towards Common Stockholders Growth (3y) (2026)
Powered by 
Analysis
Radiopharm Theranostics (RDPTF) Net Income towards Common Stockholders Growth (3y) (2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn | 19.87% |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | -129.59% |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn | 6.30% |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | 10.23% |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | 91.31% |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn | 17.25% |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | 37.44% |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | -45.23% |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn | - |
| 10 | Radiopharm Theranostics | 23.65 Mn | 23.60 Mn | -92,644.38 | 72.59% |